103 studies found for:    "idiopathic inflammatory myopathy"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Not yet recruiting MYOPROSP - a Prospective Cohort Study in Myositis
Conditions: Myositis;   Idiopathic Inflammatory Myopathy
Intervention:
2 Unknown  A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy
Condition: Idiopathic Inflammatory Myopathy
Intervention:
3 Recruiting Environmental Risk Factors for Myositis in Military Personnel
Conditions: Dermatomyositis;   Adult Polymyositis;   Inclusion Body Myositis;   Myositis
Intervention:
4 Recruiting Adult and Juvenile Myositis
Conditions: Dermatomyositis;   Polymyositis;   Inclusion Body Myositis
Intervention:
5 Completed Immune Abnormalities in Sporadic Inclusion Body Myositis
Conditions: Sporadic;   Inclusion Body;   Myositis
Intervention:
6 Completed Alemtuzumab to Treat Sporadic Inclusion Body Myositis
Condition: Myositis, Inclusion Body
Intervention: Drug: Alemtuzumab (Campath)
7 Completed Arimoclomol in Sporadic Inclusion Body Myositis
Condition: Inclusion Body Myositis
Interventions: Drug: Arimoclomol;   Other: Placebo
8 Recruiting Belimumab in Myositis
Condition: Myositis
Intervention: Drug: Belimumab/Placebo + standard of care (randomized phase)
9 Completed Lithium in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis
Intervention:
10 Completed Anakinra in Myositis
Conditions: Polymyositis;   Dermatomyositis;   Inclusion Body Myositis
Intervention: Drug: Anakinra
11 Active, not recruiting Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
Conditions: Becker Muscular Dystrophy;   Sporadic Inclusion Body Myositis
Intervention: Biological: rAAV1.CMV.huFollistatin344
12 Active, not recruiting Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis (sIBM)
Intervention: Drug: BYM338 (Bimagrumab)
13 Completed Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis
Interventions: Biological: BYM338;   Biological: Placebo
14 Recruiting An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
Condition: Sporadic Inclusion Body Myositis
Interventions: Drug: Bimagrumab;   Drug: Placebo
15 Recruiting Natalizumab in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis (IBM)
Intervention: Drug: Natalizumab
16 Not yet recruiting Study of Arimoclomol in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis
Interventions: Drug: Arimoclomol;   Other: Placebo
17 Completed Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis
Condition: Inclusion Body Myositis
Intervention:
18 Completed Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Condition: Inclusion Body Myositis
Intervention: Drug: Etanercept
19 Completed Blood-flow Restricted Exercise in Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis
Interventions: Other: Blood-flow restricted training;   Drug: Care as usual
20 Recruiting Exercise in Sjogren, Myositis and Takayasu's Arteritis
Conditions: Primary Sjogren´s Syndrome;   Myositis
Intervention: Other: Exercise training

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years